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Purpose
This study was aimed to investigate the role of poly(A)-binding protein-interacting protein 1
(Paip1) in cervical carcinogenesis.
Materials and Methods
The expression of Paip1 in normal cervical epithelial tissues and cervical cancer (CC) tissues
were detected by immunohistochemistry. In vivo and in vitro assays were performed to val-
idate effect of Paip1 on CC progression.
Results
Paip1 was found to be up-regulated in CC, which was linked with shorter survival. Knock-
down of Paip1 inhibited cell growth, induced apoptosis and cell cycle arrest in CC cells,
whereas its overexpression reversed these effects. The in vivo tumor model confirmed the
pro-tumor role of Paip1 in CC growth. 
Conclusion
Altogether, the investigation demonstrated the clinical significance of Paip1 expression,
which prompted that the up-regulated of Paip1 can presumably be a potential prognostic
and progression marker for CC.
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Introduction
Cervical cancer (CC) is the fourth most common cause of
cancer in women worldwide [1-3]. With the increasing 
uptake of Pap smear screening and hepatitis B virus vaccines
in recent years, the incidence of CC has been decreased in
many countries [4,5]. However, there are still approximately
527,600 new cases and 265,700 deaths worldwide in 2012. 
Especially in developing countries, CC ranks as the second
most commonly diagnosed cancer and the third leading
cause of cancer death [6]. Unfortunately, there are no definite
diagnostic and prognostic biomarkers [7].
Poly(A)-binding protein-interacting protein 1 (Paip1) is a
479-residue protein which encoded by PAIP1. Paip1 was 
involved in the initiation of translation in eukaryotes by
binding polyadenylate-binding protein cytoplasmic 1 and
several eukaryotic initiation factors 4F complexes [8,9]. Paip1
stimulated translation rates and therefore implicated in sev-
eral pathogenic roles [10,11]. Scotto et al. [12] mentioned that
Paip1 was up-regulated in invasive CCs and played a role in
DNA repair and cell cycle regulation. Subsequently, Piao et
al. [13] reported that Paip1 was found to be overexpressed
in breast cancer, and its expression was closely related to cell
cycle and poor prognosis. These results indicated that target-
ing Paip1 might be an effective anti-tumor therapy strategy.
However, the biological role and related mechanisms of
Paip1 in CC progression have not been studied.
Therefore, our data examined the relationship between
Paip1 overexpression and clinicopathological features of CC
and assessed its prognostic value. We also observed that
Paip1 promoted CC cell proliferation, arrested cell cycle pro-
gression and inhibited cell apoptosis. These studies have pro-
moted our understanding of the role of Paip1 in CC deve-
lopment and its related molecular mechanisms.
Materials and Methods
1. Reagents
Antibodies against Paip1, cyclin B1, CDK1, P21, Bax, Bcl-
2, and actin were purchased from Proteintech Technology
(Wuhan, China). Antibody against Ki-67 was purchased
from BOSTER (Wuhan, China).
2. Clinical samples
Routinely diagnosed primary CC tissues (130 cases: squa-
mous cervical cancers, 121; adenocarcinomas, 9), cervical 
intraepithelial neoplasia (CIN) tissues (CIN-1, 22; CIN-2, 34;
CIN-3, 38) and normal cervical epithelial tissues (47 cases)
with clinical features were collected in the present study. All
tissue specimens were taken from patients who underwent
CC surgery and who did not receive any preoperative tumor
therapy. Diagnosis and staging were based on the Staging
Manual of the American Joint Committee on Cancer, 7th edi-
tion. Clinical information on the samples is summarized in
Tables 1 and 2.
3. Cell culture and stable cell line establishment
The human CC cell lines (SiHa, HeLa, C33A, and Caski)
and normal non-malignant breast cells (MCF-10A) (Ameri-
can Type Culture Collection, Manassas, VA) were cultured
in Dulbecco's modified Eagle medium containing 10% fetal
bovine serum and streptomycin-penicillin (100 U/mL). Cells
were incubated at 37°C in an atmosphere of 5% CO2.
Stable knockdown of Paip1 was generated by transducing
the sh-Paip1 lentiviral expression construct in cells (Gene-
chem, Shanghai, China). The shRNA sequence used was the
following: 5!-GCTTCTATGCC TACAACTT-3!. Stable lenti-
viral transfected SiHa and HeLa were selected using 2 µg/mL
puromycin for 2 weeks. Transfection efficiency was con-
firmed by western blot. Human Paip1 cDNA was purchased
form (Genechem) and cloned into the GV144 plasmid. The
Paip1 plasmid and corresponding empty vector were trans-
fected into CC cell (C33A) using Lipofectamine 3000 reagent
(Invitrogen, Carlsbad, CA) following the manufacturer’s pro-
tocol.
4. Western blot
Western blot and protein detection was performed as pre-
viously described [14]. The harvested cells were prepared
with RIPA cell lysis buffer containing a protease inhibitor
mixture, and then run on sodium dodecyl sulfate polyacry-
lamide gel electrophoresis and transferred to polyvinylidene
difluoride membranes (Immobilon P, Millipore, Bedford,
MA), probed with primary antibodies and second antibodies.
At last, the results were analyzed quantitatively using chemi-
luminescent and fluorescent imaging system.
5. MTT assay
Cells were plated into 96-well plates and cultured with 
indicated compounds for 0, 24, 48, and 72 hours, followed by
the addition of 100 µL of MTT solution to each well and fur-
ther incubation for 4 hours. Removed the medium from the
wells and added 100 µL dimethyl sulfoxide into each well.
The relative number of surviving cells was assessed by meas-
uring the absorbance at 570 nm.
6. Colony-forming assay
Cells were plated on 6-well plates at a concentration of
5,000 cells for each well and the medium was replaced every
3 days. Cells were fixed and stained with 1% crystal violet
after incubating for 2 weeks.
7. Flow cytometry assay
Cell cycle status was determined by measuring cellular
DNA content after staining with propidium iodide (PI; BD
Bioscience, San Jose, CA). Briefly, cells in the log growth
phase were seeded at a density of 2!105 cells per well in 
6-well plates. After treatment, cells were harvested and fixed
in 70% cold ethanol at –20°C overnight. The next day, cells
were treated with 100 µg/mL of RNase and incubated at
37°C for 30 minutes. Then, cells stained with 100 µg/mL of
PI in the dark at room temperature, for another 30 minutes.
Samples were subsequently analyzed with the FACScalibur
Cancer Res Treat. 2019;51(4):1653-1665
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flow cytometer (BD Bioscience), and data were analyzed
with ModFit LT software (Verity Software House, Topsham,
ME).
Apoptosis was evaluated in CC cells with Annexin V-FITC
and PI staining (20 minutes; BD Biosciences). Cells were 
analyzed using a flow cytometer (BD Biosciences) according
to the manufacturer’s instructions [15].
8. In vivo tumorigenesis assays
BALB/c nude mice were housed in specific pathogen-free
conditions following the guidelines of the Institutional Ani-
mal Care. To assess the effect of Paip1 on tumorigenicity in
vivo, CC cells were subcutaneously injected into the left or
right flank of the mice. Animals were sacrificed after 6 weeks
of treatment, and then the mean tumor weight was meas-
ured. Tumor sizes were measured every 7 days.
9. Immunohistochemical staining
For Immunohistochemical (IHC) studies with a DAKO
LSAB kit (DAKO A/S, Glostrup, Denmark), tissue sections
were deparaffinized, rehydrated and incubated with 3%
H2O2 in methanol for 15 minutes at room temperature (RT)
to eliminate endogenous peroxidase activity. Antigen retri-
eval was performed by placing the slides in 0.01 M sodium
citrate buffer (pH 6.0) at 95°C for 20 minutes. The slides were
then incubated with the primary antibody at 4°C overnight.
After incubation with the secondary antibody at RT for 1
hour, immunostaining was developed using DAB, and the
slides were counterstained with hematoxylin [16].
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Diagnosis No. of cases
Paip1 protein expression Positive Strongly 
– + ++ +++ rate (%) positive rate (%)
Normal cervix 47 40 5 2 0 14.9 4.3
CIN-1 22 11 5 5 1 50.0* 27.3*
CIN-2 34 14 9 7 4 58.8** 32.4*
CIN-3 38 13 10 10 5 65.8** 39.5**
CC 130 27 31 30 42 79.2** 55.4**
Paip1, poly(A)-binding protein-interacting protein 1; CIN, cervical intraepithelial neoplasia. *p < 0.05 and **p < 0.01, com-
pared with normal cervical epithelial tissues.
Table 1. Paip1 protein expression in cervical cancers
Table 2.  Correlation between Paip1 expression and the clinicopathological features of cervical cancers
Paip1, poly(A)-binding protein-interacting protein 1; SCC, squamous cervical cancer; AC, adenocacinoma; LN, lymph node.
Variable No. of cases Paip1 strongly positive cases, n (%) !2 p-value
Age (yr)
< 50 78 42 (53.8) 0.187 0.666
! 50 52 30 (57.7)
Histological types
SCC 121 66 (54.5) 0.498 0.480
AC 9 6 (66.7)
Stage
0-II 82 39 (47.6) 5.501 0.019
III-IV 48 33 (68.8)
Differentiation
Well 44 17 (38.6) 8.562 0.014
Moderately 38 22 (57.9)
Poorly 48 33 (68.8)
LN metastasis
Negative 58 25 (43.1) 6.392 0.011
Positive 72 47 (65.3)
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Fig. 1.  Poly(A)-binding protein-interacting protein 1 (Paip1) expression was significantly up-regulated in cervical cancer
(CC). (A, B) Analysis of Paip1 expression in Oncomine data set. (C) Paip1 protein staining was negative in cervical epithelial
tissues. (D, E) Paip1 protein staining was positive in dysplastic cells of cervical intraepithelial neoplasia. (F) Paip1 protein
staining was positive in adenocarcinoma. (G, H) Paip1 protein staining was positive in squamous cervical cancers. (I) Rela-
tionship between Paip1 expression and clinicopathological significance of CCs. LN, lymph node.
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10. Evaluation of IHC staining
Statistics of IHC scores were conducted according to the
ratio and intensity of positive-staining areas. Staining areas
were scored as ‘0’ (negative, no or less than 5% positive cells),
‘1’ (6%-25% positive cells), ‘2’ (26%-50% positive cells), ‘3’
(50%-75% positive cells), and ‘4’ (more than 75% positive
cells). And the staining intensities were scored as ‘0’ (no
staining), ‘1’ (weak staining), ‘2’ (moderate staining), and ‘3’
(intense staining). A final score was calculated by multiply-
ing these two parameters. All slides were scored independ-
ently by two pathologists, who were blind to all clinical data.
11. Statistical analysis
The data analysis was performed using SPSS ver. 17.0 soft-
ware (SPSS Inc., Chicago, IL) and GraphPad Prism 6.0 soft-
ware (GraphPad Software Inc., San Diego, CA). Group
comparisons for continuous data were done by t test or one-
way ANOVA. Biochemical experiments were performed in
triplicate and a minimum of three independent experiments
were evaluated. The value of p < 0.05 was considered statis-
tically significant.
12. Ethical statement
This study complied with the principles of the Declaration
of Helsinki and was approved by the human ethics and 
research ethics committees of Yanbian University Medical
College in China. The resected specimens from patients who
underwent surgery were potentially used for scientific 
researches and publication of identifying information/
images (when applicable). Their privacy will be maintained.
The follow-up survival data were collected retrospectively
through medical-record analyses.
All experiments were performed in keeping with the pro-
cedures and protocols of the Animal Ethics Committee of
Yanbian University.
Results
1. Paip1 up-regulated in CC
The Oncomine data sets revealed the fact that Paip1 
expression was augmented in tumor tissues in comparison
with the normal cervical tissues (p < 0.01) (Fig. 1A and B). To
verify of the informatic data, Paip1 expression in a group
which consisted 130 cases of CC, 94 cases of CIN and 47 nor-
mal cervical tissues was figured out using IHC, and it was
validated that Paip1 exhibited remarkable expression levels
in CC tissues when compared with normal cervical epithelial
tissues (Fig. 1C-H, S1 Fig.). Here, the positive rate of Paip1
expression was only 14.9% (7/47) in normal cervical epithe-
lial tissues, but significantly higher in CIN lesions (50.00% in
CIN-1, 58.8% in CIN-2, and 65.8% in CIN-3) and CC (79.2%,
90/174) (p < 0.05, respectively). Similarly, the strongly posi-
tive rate of Paip1 expression was observed in 55.4% (72/130)
of CCs, which was significantly higher than in normal cervi-
cal epithelial tissues (4.3%, 2/47) (p < 0.01) (Table 1).
The correlations between Paip1 expression and clinico-
pathologic features were shown in Table 2. The high expres-
sion of Paip1 in CCs was significantly correlated with the
clinical stage (p=0.019), differentiation (p=0.014), and lymph
node metastasis (p=0.011) (Fig. 1I), but not with other factors
included age or histological types. In all, these results indi-
Cancer Res Treat. 2019;51(4):1653-1665
Table 3.  Cox regression model analysis of the clinicopathological features in 130 patients with cervical cancer
B, coefficient; SE, standard error; Wald, Wald statistic; HR, hazard ratio; CI, confidence interval; LN, lymph node; Paip1,
poly(A)-binding protein-interacting protein 1.
Characteristic B SE Wald HR 95% CI p-value
Univariate
Age 0.154 0.183 0.708 1.166 0.815-1.669 0.400
Stage 0.551 0.188 8.595 1.735 1.200-2.507 0.003
Differentiation 0.178 0.114 2.437 1.194 0.956-1.493 0.118
LN metastasis 0.388 0.178 4.745 1.474 1.040-2.091 0.029
Paip1 0.932 0.191 23.764 2.540 1.746-3.694 0.000
Multivariate
Stage 0.557 0.215 6.743 1.746 1.146-2.658 0.009
LN metastasis 0.317 0.203 2.442 1.373 0.923-2.043 0.118
Paip1 1.076 0.203 28.097 2.932 1.970-4.364 0.000
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cated that high-level expression of Paip1 appears to be asso-
ciated with CC progression.
2. Elevated Paip1 expression correlated with poor progno-
sis in CC patients
Since we have confirmed the correlation between high
Paip1 expression and CC progression, we next explored the
potential roles of Paip1 in CC patients’ clinical outcome. By
Nan Li, Paip1 Expression in Cervical Carcinoma
Fig. 3.  Poly(A)-binding protein-interacting protein 1 (Paip1) attenuated the ability of proliferation of cervical cancer (CC)
cells in vitro. (A) The protein expression of Paip1 in CC cells was examined by western blot analysis. Actin was used as a
loading control. (B) The protein expression of Paip1 in the constructed CC cells was confirmed by western blot analysis.
Actin was used as a loading control. (C, D) Cell proliferation was examined by MTT (C) and colony formation (D) in the
constructed cells. Data are represented as mean±standard error of mean of at least three independent experiments, **p < 0.01.
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using The Human Protein Atlas, we showed that CC patients
with high expression of Paip1 displayed a poor overall sur-
vival (OS) (Fig. 2A). Then Kaplan-Meier survival curves sug-
gested that patients with high Paip1 expression had signi-
ficantly shorter disease-free survival (DFS; p < 0.001) (Fig. 2B)
and OS (p < 0.001) (Fig. 2C). Additionally, CC patients with
overexpression of Paip1 had decreased DFS and OS com-
pared to those with low Paip1 expression in either early-
stage or late-stage cases (both p < 0.05) (Fig. 2D-G). More-
over, clinical stage, lymph node metastasis, and Paip1 expre-
ssion status were correlated with shorter survival time in uni-
variate analysis (Table 3). Multivariate Cox regression ana-
lysis further substantiated that Paip1 and clinical stage was
an independent risk factor for lower DFS and shortened OS
in patients with CC (Table 3). Based on the results above, we
conclude that the overexpression of Paip1 can be regarded
as a poor prognostic index in CC.
3. Paip1 promoted the proliferation of CC cells
To investigate its potential function in CC progression, we
firstly examined the expression of Paip1 in CC cell lines by
western blot, and then stably knocked down Paip1 in high
Paip1-expressing cells (SiHa and HeLa), and overexpressed
Paip1 in low Paip1-expressing cell (C33A) (Fig. 3A). The 
expression levels of Paip1 in transfected cells were verified
by western blot (Fig. 3B). Then, we assessed cell growth by
MTT assays and found that CC cell lines with decreased
Paip1 expression had slower growth rates, while CC cell lines
with increased Paip1 expression had higher growth rates
(Fig. 3C, S2A Fig.). Next, as determined by colony formation
assays, Paip1 knockdown reduced the number of colonies
formed, while Paip1 overexpression enhanced (Fig. 3D, S2B
Fig. S3 Fig.). These results indicated that Paip1 promote the
proliferation of CC cells in vitro.
4. Paip1 knockdown induced cell cycle arrested and apop-
tosis
For the purpose of decided on whether the impact of Paip1
on CC cell proliferation was the key observations of the
Paip1-mediated alternations in the progression of the cell
cycle, we carried out the flow cytometry assay in CC cell
lines. As suggested by our observations, Paip1 knockdown
gave rise to increased G2/M phase together with decreased
G1 phase, as compared with the control cells (Fig. 4A). In 
addition, Paip1 knockdown altered the expression pattern of
the key regulators that were indispensable in G2/M cell cycle
regulation. Western blotting results indicated that cyclin B1
and CDK1 were decreased after Paip1 silencing, while 
cyclin-dependent kinase inhibitor P21, which was identified
as tumor suppressor [17], was increased in the sh-Paip1
group (Fig. 4B, S2D-S2E Fig.). Conversely, the opposite effect
was found in Paip1 overexpressed cells (Fig. 4A and B).
Subsequently, in order to study whether Paip1 can affect
the apoptosis of CC cell lines, we carried out the flow cytom-
etry assay in CC cell lines. As highlighted by the flow cytom-
etry assay, Paip1 knockdown cells manifested higher apop-
totic rate in comparison with the control group, whereas
Paip1 overexpression displayed the opposite effect in CC
cells (Fig. 5A, S2C Fig.). To further investigate which apop-
tosis pathway components were involved in CC cells res-
ponse to Paip1 knockdown [18], we detected the expression
of apoptosis-associated molecules by western blot. As shown
in Fig. 5B, a marked increase in the pro-apoptotic Bax, and
decrease in the anti-apoptotic Bcl-2 was observed after Paip1
knockdown. Meanwhile, the overexpression of Paip1 per-
formed reserved trend (Fig. 5B). Collectively, Paip1 not only
inhibited cell apoptosis and regulated cell cycle progression
of CC cell lines, but also promote cell proliferation.
5. Paip1 promoted CC growth in vivo
To further verify the cellular function of Paip1 in vivo, a
xenograft mouse model was employed to study the role of
Paip1 in CC growth. There was good agreement between in
vivo and in vitro data. CC cells with stable knockdown or
overexpression Paip1 were injected into nude mice, tumors
derived from Paip1 knockdown group grew slower, and the
average tumor weight was significantly lower. While tumor
volume was markedly higher, and tumors were also heavier
in mice which inoculated with Paip1 overexpressed cells
(Fig. 6A and B, S4 Fig.). Next, we performed immunohisto-
chemistry for Ki67, Bcl-2, and Bax in the xenografted tissues.
As expected, knockdown Paip1 decreased the number Ki67
positive cells, reduced the expression of Bcl-2, and up-regu-
lated the expression of Bax (Fig. 6C, S5 Fig.). The result was
further confirmed in Paip1 overexpressed group (Fig. 6C, 
S5 Fig.). In conclusion, as an oncogene, Paip1 performs a sub-
stantial function in CC proliferation.
Discussion
The regulation of gene expression occurs in the process of
mRNA translation of eukaryotes, particularly at the transla-
tion initiation [19,20]. Deregulation at this step of the trans-
lation process results in abnormal expression of genes, which
in turn changes cell growth and may lead to the development
of cancer [21,22]. As a translational enhancer, Paip1 can stim-
ulate translation rates in vivo, which have a promoter func-
tion in several tumors [11]. Besides, PAIP1 also plays a role
Cancer Res Treat. 2019;51(4):1653-1665
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in the decay of RNA. Grosset et al. [23] demonstrated that
Paip1 was identified as one of the five mCRD-associated pro-
teins. These proteins can form a multi-protein complex, sta-
bilized mCRD-containing mRNA by impeding deadeny-
lation. Nevertheless, the role of Paip1 in CC is still considered
to be part of a growing sphere, which needs further investi-
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Fig. 6.  Poly(A)-binding protein-interacting protein 1 (Paip1) promoted tumor growth in vivo. (A, B) Indicated cells were 
injected into the nude mice, and statistical comparison of the differences in tumor weight was shown. (C, D) Expression
levels of Ki-67, Bcl-2, and Bax in the xenograft tumors tissues were detected by immunohistochemistry.
C
Ki-67
Bcl-2
Bax
sh-Con sh-Paip1
SiHa
D
Ki-67
Bcl-2
Bax
Vector Paip1
C33A
sh-Con
sh-Paip1
A
500
0
200
100
300
400
Tu
m
or
 w
ei
gh
t (
m
g)
sh-Paip1sh-Con
sh-Con sh-Paip1
Vector
Paip1
B
600
500
0
200
100
300
400
Tu
m
or
 w
ei
gh
t (
m
g)
Paip1Vector
Vector Paip1
VOLUME 51 NUMBER 4 OCTOBER 2019 1663
gation. Through this study, we identified for the first time
the function of Paip1 in CC progression and the underlying
mechanism.
We firstly studied the clinicopathological significance of
Paip1 in CC, by performing immunohistochemistry. Accord-
ing to our results, Paip1 may have a tumor promoter func-
tion, and its expression could be a crucial prognostic indi-
cator in CC. Our data showed that the expression of Paip1
was significantly elevated in CC tissues, while being absent
in normal tissues. More importantly, the high Paip1 expres-
sion level was significantly associated with some clinico-
pathological parameters like clinical stage, differentiation,
and lymph node metastasis. However, no differences were
found with age or histological types. In particular, we found
that CC patients exhibiting high Paip1 expression had poorer
OS and DFS than patients with low expression. As a result,
we believed that Paip1 plays a crucial role in patient prog-
nosis, and the overexpression of Paip1 was an important
characteristic in CC occurrence and progression.
Previous studies reported that Paip1 was overexpressed in
breast cancer and can promote tumor-cell growth [13]. Con-
sistent with these findings, our in vitro and in vivo studies
have demonstrated a strong role of Paip1 in CC growth.
Since cell cycle progression was a key step for tumor growth,
and the aberrant cell cycle was closely related to the occur-
rence and development of cancers [24]. So, we assessed the
change of cell cycle in CC cells transfect with or without
Paip1, and found that Paip1 knockdown leads to G2/M cell
cycle arrested, while Paip1 overexpression exhibited the 
opposite results. Moreover, we detected the change of cycle-
related proteins cyclin B1 and CDK1, which were responsible
for the transition of the cell from the G2 to the M phase and
their down-regulation would lead to G2/M cell cycle arrest
[25]. As indicated by our data, Paip1 knockdown led to 
decreased expression of the cyclin B1 and CDK1, whereas
Paip1 overexpression enhanced cyclin B1 and CDK1 expres-
sion. These results supported that Paip1 can control the pro-
gression of the cell cycle by regulating the expression of cell
cycle proteins, thus affected CC cell proliferation.
Apoptosis was also a critical step for tumor development,
and there were complex links between cell progression and
cell apoptosis in the tumor. Bcl-2 and Bax were respectively
anti-apoptotic and pro-apoptotic genes, and both of them 
belonged to Bcl-2 gene family [26]. Increased levels of pro-
apoptotic proteins and/or decreased anti-apoptotic proteins
can lead to apoptosis [27]. In the present report, Paip1 knock-
down was found to induce apoptosis and followed a 
decrease of Bcl-2, an increase of Bax expression. Current
thinking suggested that the ratio of Bax to Bcl-2 may play a
vital role in cell apoptosis [28]. Thus, we conclude that Paip1
might be closely bonded with the apoptosis of CC cells
through regulating the expression of apoptotic proteins,
thereby influenced the proliferation of CC cell.
To summarize, as suggested by our research, Paip1 was
overexpressed in CC samples and associated with the 
adverse outcomes in patients with CC, Paip1 knockdown 
induced inhibition of cell growth, G2/M arrest and apoptosis
in CC cells (Fig. 7). These findings may provide the potential
use of Paip1 as a therapeutic target of CC. Before that, a more
comprehensive study was urgently needed to determine the
mechanisms of Paip1 as an informative biomarker in patients
with CC.
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Fig. 7.  Schematic diagram. Poly(A)-binding protein-inter-
acting protein 1 (Paip1) enhanced proliferation and inhib-
ited apoptosis in cervical cancer.
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